# Orient Pharma Co., Ltd. Yunlin Plant – FDA Inspection, Nov 16, 2018

Source: https://www.keypedia.com/records/fda_inspections/orient-pharma-co-ltd-yunlin-plant/e457d267-6392-48cb-a24b-4e722690553b
Source feed: FDA_Inspections

> FDA inspection 1077757 of Orient Pharma Co., Ltd. Yunlin Plant, November 16, 2018. Classification: No Action Indicated (NAI). 4 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1077757
- Company Name: Orient Pharma Co., Ltd. Yunlin Plant
- Inspection Date: 2018-11-16
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1274326 - 2025-05-23
- [FDA Inspection 1062312 - 2018-07-06](https://www.keypedia.com/records/fda_inspections/orient-pharma-co-ltd-yunlin-plant/67b73ca1-769c-4cc8-b767-a5b6b3ce38bb)
- FDA Inspection 921908 - 2015-04-03
- FDA Inspection 813081 - 2012-12-14

## Related Officers

- [Company Rep](https://www.keypedia.com/people/michael-l-casner/a0f35f37-4795-4edf-a9f6-a447d64c0fd4)

Company: https://www.keypedia.com/companies/orient-pharma-co-ltd-yunlin-plant/c8cecdbc-ad8f-4820-87c2-1c2d47b95e8d

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
